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ABSTRACT 
 
Lipidots
®
 technology has thrived towards a versatile 
nanodelivery platform for designing and producing a series 
of nanoproducts for in vivo diagnostic, in vivo imaging, 
activated or non-activated targeted drug delivery. In order 
to ensure quality of final products, characterization as 
nanotherapeutics is a key parameter. Thus, we are seeking 
to implement and validate a panel of characterization 
methods significantly suitable for Lipidots
®
. More 
particularly, we have investigated the lipid quantification, 
the drug/dye encapsulation, release kinetics and leakage to 
anticipate the nanocarrier behavior in biological media.  
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1 INTRODUCTION 
 
For eight years, our research group has been developing 
lipid nanocarriers, known as Lipidots
®
, as a multifunctional 
platform for medical applications. A wide range of active 
pharmaceutical ingredients and contrast imaging agents has 
been encapsulated into Lipidots
®
 enabling the delivery of 
therapeutic agents and the monitoring or diagnosis by 
fluorescence imaging [1-2]. In addition to size and surface 
charge of the nanomaterials, as key parameters requested by 
regulatory health agencies, a more deep understanding of 
nanoparticles composition, morphology, crystallinity, drug 
loading/localization and drug release kinetics is crucial to 
meet the requirements of final medicinal nanoproducts. 
Such extensive characterization in addition to the ability to 
scale up the manufacturing process of our carriers, allows 
identifying characterization criteria and specifications to 
move towards industrial production and approval of the 
product for the clinical market. Herein, we present a full 
cascade of  physical-chemical characterization methods 
dedicated specifically to Lipidots
®
. 
 
2 RESULTS AND DISCUSSION 
 
2.1 Morphology and Physical characterization 
Lipidots
®
 are composed of a lipid core, mixture of 
soybean oil and a wax at different ratios, and a surfactant 
shell, mixture of phospholipids and PEGylated surfactants. 
Batches of particles are manufactured by ultrasonication at 
labscale. Particles with specified diameter can be produced 
depending on the lipid and surfactants ratios, as previously 
described [3-5]. For physical characterization of particles, 
Dynamic Light Scattering (DLS) was used to assess the 
particle hydrodynamic diameter, as well as their colloidal 
evolution during storage. We observed very-long term 
stability under conventional storage (room temperature), 
even at 40°C. Since the lipid emulsions are known to be 
destabilized because of coalescence destabilization [6], we 
evidenced that Ostwald ripening could be prevented by the 
use of complex mixtures for both the core lipids and the 
shell surfactants, bringing entropy mixing stabilization to 
the physico-chemical system [5]. For investigation of 
internal state of droplets, Differential Scanning Calorimetry 
(DSC) displayed no evidence of any crystallization event in 
the particle dispersions, even after prolonged storage at 4°C 
(up to 8 months), and when the core is made of wax only.  
This amorphous state should promote long-term 
encapsulation and homogeneous release of active 
ingredients from the Lipidots
®
 core. 
1
H NMR experiments 
were used to probe the viscosity of the particle core. We 
demonstrated that core composition and temperature 
appeared to be key parameters able to control the lipid core 
viscosity [4]. To characterize the shape of nanodroplets, 
CryoTEM analysis has been performed showing oblong 
particles with size distribution in agreement with that 
measured by DLS. As Flow Field Fractionation (FFF) 
technique is considered more accurate for polydispersed 
samples in physiological media, size distribution has been 
evaluated and corroborated with data obtained from both 
other techniques. 
 
2.2 Lipidots® Composition 
Suppocire NB™ (SC) is a complex mixture of mono- 
(MGs), di- (DGs) and triglycerides (TGs) of various acyl 
chain lengths (C8–C18), with an overall hydroxyl value of 
20–30%. Super RefinedTM Soybean oil (SB) is composed of 
C16-C18 unsaturated triglycerides. Based on supplier 
information, Myrj
TM
 S40 (S40) is non-ionic surfactant 
described as PEGylated stearate with distribution of 
ethylene oxide (EO) centered around 40 units. As a 
phospholipid (PL), Lipoid-s75
® 
is mainly composed of 
phosphatidylcholine (PC) blended with slight proportion of 
phosphatidylethanolamine (PE) and lysophosphatidylcholine 
(LPC) lower than 10 and 3%, respectively. 
 
 
Figure 1: UPLC-ELSD chromatograms of 50 nm-size 
Lipidots
®
, Myrj
TM 
S40, Suppocire NB
TM
 and Super 
Refined
TM
 Soybean oil.  
 
The separation and quantification of lipids belonging to the 
wax and oil were achieved using reverse-phase (RP) HPLC 
coupled with Evaporated Light Scaterring Detector 
(ELSD). Indeed, the RP-HPLC mode is the most important 
HPLC technique for the analysis of triglycerides mixture. 
The separation of TGs species is based on both the 
combined chain lengths of the fatty acyl residues and on the 
total number of double bonds in the molecule. Normal-
phase (NP)-HPLC has been also used for the separation of 
TGs, however, in most cases only as rather strongly 
overlapping peak-clusters [7]. Moroever, problems may 
occur as NP-HPLC separation methods usually use mobile 
phases consisting of unpolar solvents (like hexane, 
isooctane or chloroform) as main constituents [8]. 
Furthermore, it is possible to separate PEG fatty acid esters 
as single peak per each component with the reversed-phase 
mode [9]. ELSD was selected as detector since it has low 
background signal, a non-specific reponse, is compatible 
with gradient elution and with a broad range of solvents, 
and has a signal independent of the degree of saturation and 
chain length of fatty acids or TGs [10]. For PL 
quantification, Hydrophilic Interaction Liquid 
Chromatography (HILIC) mode is often recommended 
when combined several classes of phospholipids [11].  
 
Figure 2: UPLC-ELSD chromatogram of Lipoid-s75
®
 
obtained by using HILIC chomatography.  
 
Herein, a RP-HPLC method has been developped for the 
analysis of Lipidots
®
 mixture. In a single run (Fig. 1), we 
have sucessfully separated each component of the S40 (blue 
peaks) and the mixture of MGs, DGs and TGs from SC (red 
peaks) and SB (yellow peaks). Using mass spectrometry 
detector, the 3 peaks obtained for S40 surfactant were 
respectively assigned to PEG-OH, PEG-C16 and PEG-C18. 
For SB and SC, each peak is actually a cluster of MGs, DGs 
and TGs, which are identified by mass spectrometry. Once 
formulated into Lipidots
®
, most of the lipids can be 
identified and quantified in a single analysis which run over 
30 min with appropriate validated methods. The typical 
chromatogram obtained for Lipidots
®
 can be used to 
quantify some individual components incorporated into 
Lipidots
®
 formulation by using appropriate peaks (colored 
peaks defined on chromoatogram in Fig. 1). A “fingerprint 
approach” was established for Lipidots® nanoparticles 
based on lipid composition and content, enabling to follow 
up any evolution during manufacturing process and ageing 
of formulations. Before quantifying PLs from a Lipidots
®
 
formulation, S40 components have to be removed using 
normal phase silica SPE to avoid interferences. Baseline 
separation of three PLs classes was achieved (Fig. 2), under 
gradient conditions, within a run time of 13 min, eluting 
according to decreasing polarity, i.e.: PE > PC > LPC [12]. 
As previously used for SB, SC and S40 components, a mass 
spectrometry detection allows identifying the different sub-
components of Lipoid-s75
®
.  
 
2.3 Lipidots® Drug Localization 
NMR spectroscopy using proton NOE (Nuclear 
Overhauser Effect) measurements has been used to localize 
dyes/drugs in the lipid nanoparticles [2]. This technique can 
be easily applied to different systems as far as drug/dye 
signals can be distinguished from Lipidots
®
 signals 
(generally in range 6-9 ppm). We therefore used this 
technique to investigate for potential interactions between  
the CsA with triglycerides (lipid core), phospholipids 
(particle internal shell) or PEG surfactants (particle external 
shell). The NOE effect is in first approximation related to 
the inter-nuclear distance, since it relies on dipolar 
interaction between protons. Specific signals representative 
of the different particle components were chosen (Fig. 3). 
The specific resonances of the lipid components entering 
the LNP composition were therefore successively 
irradiated, and their magnetization, provided that the 
corresponding proton have dipolar interactions, can be 
transferred to the –NH peaks of CsA. Whatever the lipid 
component that was irradiated, NOE transfer occurred to 
the protons of the amino groups (Fig. 3). It suggests CsA 
appears located both inside the particle core and in the 
particle shell. Based on the intensity of the NOE, most of 
CsA is located inside the particle core. 
 
 
Figure 3: Localization of CsA embedded in 50 nm-size droplets 
performed by using 
1
H NMR NOEDIFF spectroscopy. 
 
2.4 Prediction of physiological behavior 
Solid phase extraction technique (SPE) has been 
successfully applied to Lipidots
® nanotherapeutic in order 
to determine leakage kinetics under storage conditions and 
the drug release profiles in different biological model 
media. Herein, we give the example of CsA loaded (high-
loading) into Lipidots
®
. Combined with colloidal stability 
measurements, validated HPLC quantification of free and 
entrapped drug previously separated by SPE was used to 
determine the stability of these nanotherapeutic systems at 
37°C either in PBS or in DMEM-10%FBS [13, 14].  
When stored at 4°C, Hydrodynamic diameter (Dh) and 
PolyDispersity Index (PDI) remain almost constant for at 
least 9 weeks. When the nanoparticles are incubated in 1X 
PBS at 37°C, Dh and PDI do not significantly. In contrast 
after incubating with DMEM-10%FBS at 37°C the 
colloidal stability can no longer be guaranteed for 96 h. For 
at least 24 h, CsA-loaded lipid nanoparticles show great 
colloidal stability since Dh and PDI remain almost constant 
for both LNPs. From 48 h, we observed a significant 
increase of PDI values (>0.3) with a bimodal distribution of 
particle size.  
Thanks to our validated tripartite SPE method, the 
%free and %entrapped CsA are determined in triplicate at 
different time-points as illustrated in Fig. 4. When stored at 
4°C, the %free and %entrapped CsA remain almost 
constant over the storage period for both LNPs (not shown). 
When the nanoparticles are incubated at 37°C in 1X PBS 
(Fig. 4(A)), the %free and %entrapped CsA of the total 
concentration are constant over the release period. When 
the nanoparticles are incubated at 37°C in DMEM-
10%FBS, the %free and %entrapped CsA do not also 
considerably change until 48 h (Fig. 4(B)). For CsA-L50, 
the %free and %entrapped CsA are equal to 46 and 50% 
(average until 48 h), respectively. For CsA-L120, %free 
and %entrapped CsA are respectively equal to 52 and 44% 
(average until 48 h). Further investigations have also 
demonstrated that the %free and %entrapped CsA were 
dilution-dependent. Indeed, we found that %free and 
%entrapped CsA were respectively 32 and 65%, for CsA-
L50 at a concentration of 10 mg/mL. 
 
 
Figure 4: Drug release profiles of 50 nm and 120 nm-size 
CsA loaded nanodroplets performed at 37°C in 1X PBS (A) 
or in DMEM-10%FBS (B). 
 
The release profile is similar whatever the 
buffer/medium used, thus indicating a biphasic mode of 
release. This suggests that the CsA may be loaded not only 
in the lipid core, but also in the shell responsible of the 
observed leakage. 
 
3 CONCLUSION 
 
Extensive characterization dedicated specifically to 
Lipidots
®
 as a nanomedicine allows identifying 
characterization criteria and specifications to move towards 
industrial production and approval of the product for the 
clinical market. Very recently our group has begun to 
coordinate the European nanomedicine characterization 
platform (EU-NCL). Connected to a trans-disciplinary 
testing infrastructure, this platform will propose a cascade 
of assays for the pre-clinical characterization of medical 
nanoparticles, promoting the translation of nanoproducts 
towards clinical evaluation more rapidly and for lower cost 
and also paving the way for future pre-normative activities 
in order to regulate the development of nanomedicines. 
 
4 EXPERIMENTAL SECTION 
 
4.1 Lipidots® Processing  
The nanoemulsion processing has already been detailed 
elsewhere [3-5, 15]. Briefly, lipid phase is prepared by 
mixing solid (Suppocire NC, Gattefossé) and/or liquid 
(Super-refined Soybean oil, Croda) glycerides, Lipoid s75 
(Lipoid GmbH), and eventually the compound to be loaded 
in the Lipidots
®
. The aqueous phase is composed of Myrj
TM
 
S40 (Croda) and aqueous buffer (usually 1X PBS). After 
homogeneization at 45°C, both phases are crudely mixed 
and sonication cycles are performed for 5 minutes. Non-
encapsulated components are separated by overnight 
dialysis (MWCO: 12 kDa). Lipidots
®
 dispersions are 
filtered through a 0.22 μm cellulose Millipore membrane 
before use. CsA free drug was incorporated into lipid core 
by solvent-mediated dissolution from 75 mg/mL CsA 
solution, as previously described [13]. CsA drug was 
loaded until a concentration of 3825 µg/mL and 5079 
µg/mL (for 60 mg/mL of lipids), respectively for 50-nm 
and 120-nm nanodroplets. Due to low solubility of CsA as 
free drug in aqueous buffer, dialysis purification was 
extended until 72 h with extensive changes of buffers.  
 
4.2 Morphology and structure measurements 
The hydrodynamic diameter are measured with a 
Malvern Zeta Sizer Nano instrument (NanoZS, Malvern, 
UK) in 0.1 X PBS buffer. DSC thermograms and 
1
H NMR 
spectra have respectively been recorded on a TA Q200 
system (TA instrument, France) and a Bruker Avance DPX 
500 spectrometer (Bruker, Germany), operating at 
500 MHz for proton.  
 
4.3 Determination of Lipidots® composition 
The chromatographic analysis of the Lipidots
® 
components was performed using an Acquity UPLC
®
 H-
Class system (Waters) coupled with an Alltech 3300 
Evaporating Light Scattering detector (ELSD, Grace). 
Separation of the different compounds was achieved either 
with CORTECS RP-18 or HILIC (1.6 µm, 150 x 2.1 mm) 
columns. In reversed-phase mode, the separation was 
performed with a gradient program of water, methanol and 
a mixture of isopropanol/acetonitrile : 75/25 (v/v). Samples 
was diluted with a mixture of CHCl3/MeOH:2/1 (v/v). The 
drift tube was maintained at 45°C with a flow of N2 fixed at 
2.0 L/min. In HILIC mode, the separation was performed 
with a gradient program of  acetonitrile/ammonium 
formate, 10 mM, pH3: 95/5 and 50/50 (v/v). Sample 
(Lipoid-s75
®
) was dissolved in methanol. The drift tube 
was maintained at 35°C with a flow of N2 fixed at 
1.3 L/min. Whatever the chomatography mode, the injected 
volume was 5 µL and the column temperature was fixed at 
40°C.  
 
4.4 NMR spectroscopy for CsA localization  
1
H NMR Nuclear Overhauser Enhancements difference 
(NOEDIFF) spectra of CsA-loaded lipid nanoparticles were 
recorded using the spectrometer described above. To avoid 
signal saturation arising from the intense proton signals of 
the bulk nanodroplets component, the basic sequence was 
modified by changing the last reading in proton impulsion 
in the sequence by a selective pulse. This selective pulse 
was calibrated to excite selectively a spectral range from 6 
to 9 ppm, which corresponds to NMR signals of the proton 
in –NH group. Then a series of spectra were recorded by 
irradiating the specific peaks of interest, corresponding to 
each lipid nanoparticles component. A control spectrum 
(off-resonance) was also recorded by performing the same 
experiment with an irradiation at a frequency outside the 
range of any NMR signals (-2000 Hz). Prior to the 
measurement, 300 µL of deuterium oxide was mixed with 
600 µL of nanoparticle suspension at a concentration of 
60 mg/mL of lipids.  
 
4.5 Leakage and release studies of CsA 
The protocol used for the determination of CsA release 
and leakage was based on our previous tripartite SPE 
method [13, 14]. The separation between the entrapped CsA 
and free CsA was performed by using SPE-cartridges 
Oasis
®
 HLB (6 mL, 150 mg, 80 Å, 60 µm). The leakage 
study was achieved for samples of CsA-loaded 50 nm and 
120 nm-size Lipidots
®
, which were stored in 1X PBS at 
4°C at a nanoparticle concentration of 60 mg/mL of lipids. 
Starting from the freshly prepared suspensions, leakage 
study was recorded weekly during 9 weeks. Release study 
was achieved at 37°C under gentle stirring at a nanoparticle 
concentration of 2 mg/mL either in 1X PBS or in DMEM 
containing 10% of FBS. Leakage and release profiles were 
determined by implementing SPE procedure following by 
HPLC-UV quantification. Validation of the tripartite SPE 
method has been performed according to ICH guidelines 
Q2(R1) [16] for both LNPs either in PBS or in DMEM-
10%FBS. Size distribution of Lipidots
®
 was monitored by 
DLS during the release and leakage study.  
 
REFERENCES 
 
[1] Navarro et al, J Photochem Photobiol B, 130, 161-169, 2014 
[2] Mérian et al, Eur J Pharm Biopharm, 93, 1–10, 2015 
[3] Delmas et al, Langmuir, 27, 1683–1692, 2011 
[4] Delmas et al, J Colloid Interface Sci, 360, 471–481, 2011 
[5] Goutayer et al, Eur J Pharm Biopharm, 75, 137–147,  2010 
[6] Poulin et al, Phys Rev Lett, 79, 3290–3293, 1997 
[7] Andrikopoulos, Food Rev Int, 18, 71–102, 2002 
[8] Fagan et al, J Chromatogr A, 1054, 241–249, 2004 
[9] Lee et al, Talanta, 74, 1615–1620, 2008 
[10] Rombaut et al, J Am Oil Chem Soc, 86, 19–25, 2009 
[11] Schwalbe et al, J Chromatogr A, 1217, 5179–5183, 2010 
[12] Donato et al, J Chromatogr A, 1218, 6476–6482, 2011 
[13] Guillot et al, Pharm Res, 32, 3999–4009, 2015 
[14] Couffin et al, Gut, in preparation 
[15] Texier et al, J Biomed Opt, 14, 2009 
[16] “ICH guideline Q2(R1) : Validation of Analytical 
Procedures : Text and Methodology.” 2005 
 
